Cargando…
P-Glycoprotein–Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium
Recent studies have illustrated the burden Cryptosporidium infection places on the lives of malnourished children and immunocompromised individuals. Treatment options remain limited, and efforts to develop a new therapeutic are currently underway. However, there are unresolved questions about the id...
Autores principales: | Arnold, Samuel L M, Choi, Ryan, Hulverson, Matthew A, Whitman, Grant R, Mccloskey, Molly C, Dorr, Carlie S, Vidadala, Rama S R, Khatod, Mansi, Morada, Mary, Barrett, Lynn K, Maly, Dustin J, Yarlett, Nigel, Van Voorhis, Wesley C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736360/ https://www.ncbi.nlm.nih.gov/pubmed/31180118 http://dx.doi.org/10.1093/infdis/jiz269 |
Ejemplares similares
-
Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection
por: Arnold, Samuel L. M., et al.
Publicado: (2017) -
Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro
por: Shrestha, Aruna, et al.
Publicado: (2019) -
Prevalence and Correlates of Cryptosporidium Infections in Kenyan Children With Diarrhea and Their Primary Caregivers
por: Deichsel, Emily L, et al.
Publicado: (2020) -
Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum
por: Hennessey, Kelly M., et al.
Publicado: (2018) -
Identification
of and Structural Insights into Hit
Compounds Targeting N-Myristoyltransferase
for Cryptosporidium Drug Development
por: Fenwick, Michael K., et al.
Publicado: (2023)